Immunic (IMUX) Net Cash Flow (2013 - 2026)

Immunic (IMUX) has 14 years of Net Cash Flow data on file, last reported at $171.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 885.13% year-over-year to $171.3 million; the trailing twelve-month figure through Mar 2026 stood at $172.8 million (up 308.72% YoY), and the FY2025 full-year result was -$20.4 million, down 94.39% from the prior year.
• Net Cash Flow improved to $171.3 million in Q1 2026, from -$19.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $171.3 million in Q1 2026 to a low of -$22.9 million in Q4 2024.
• A 5-year average of $5.9 million and a median of -$14.1 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 257.84% in 2023 and surged 885.13% in 2026, its largest moves.
• Tracing IMUX's Net Cash Flow over 5 years: stood at $31.3 million in 2022, then sank by 143.4% to -$13.6 million in 2023, then sank by 68.45% to -$22.9 million in 2024, then increased by 15.97% to -$19.2 million in 2025, then soared by 990.86% to $171.3 million in 2026.
• Business Quant data shows IMUX's Net Cash Flow at $171.3 million in Q1 2026, -$19.2 million in Q4 2025, and -$20.2 million in Q3 2025.